ulcerogenic

Nicotredole (Tryptamide) (Tryptamide) is an orally active analgesic and anti-inflammatory agent. Nicotredole exhibits evident anti-inflammatory effects of potency comparable with Phenylbutazone. Nicotredole has only weak ulcerogenic activity.

Talniflumate (Somalgen) is a calcium-activated chloride channel (hCLCA1/mCLCA3) blocker that reduces mucin synthesis and releases in animal models and cell culture. It possesses anti-inflammatory actions via inhibition of Cox (cyclooxygenase) and inhibits Cl-/HCO3- exchange activity. It also increases survival in a cystic fibrosis mouse model of the distal intestinal obstructive syndrome.

Zidometacin is a non-steroidal anti-inflammatory drug (NSAID) that significantly inhibits the synthesis of prostaglandins with minimal gastrointestinal damage. It has analgesic and antipyretic effects and shows a relatively low ulcerogenic potential in rat models. Zidometacin can be used for research in analgesia and osteoarthritis.

(±)-Glaziovine is a natural alkaloid used in research related to the life sciences.

M-5011 is a non-steroidal anti-inflammatory drug and immunomodulator potentially for the treatment of inflammation and pain. M-5011 had an effective antinociceptive activity (ED50 value) of 0.63 mg/kg. M-5011 partially inhibits the generalized bone loss a

Gaultherin has analgesic, and anti-inflammatory activities.Gaultherin lacks gastric ulcerogenic effect, because of it released salicylate in intestine slowly, not in stomach and it left the cyclooxygenase-1 unaffected, which was the source of cytoprotecti

COX-2-IN-7 (compound 4a) is a potent and selective COX-2 inhibitor with greater selectivity than Celecoxib and an IC50 value of 6.585 µM. It exhibits good anti-inflammatory properties and low ulcerogenic activity in vivo[1].

iNOS/PGE2-IN-1 is an iNOS/PGE2 inhibitor and a potent anti-inflammatory agent. iNOS/PGE2-IN-1 exhibits an inhibitory effect on LPS-induced NO production and has a low ulcerogenic potential.

COX-2-IN-23 is a selective inhibitor of COX-2, with IC50 values of 0.28 and 20.14 μM for COX-2 and COX-1, respectively.COX-2-IN-23 exhibits anti-inflammatory effects as well as low ulcerogenic effects.

COX-2-IN-9 is a selective, potent, orally active COX-2 inhibitor (IC50: 10.17 μM).COX-2-IN-9 has a higher COX-2 selectivity than Celecoxib.COX-2-IN-9 exhibits good in vivo anti-inflammatory activity and low ulcerogenic effect.

COX-2-IN-24 is an orally active COX-2 inhibitor [IC50: 0.17 μM] with anti-inflammatory and hypo-ulcerogenic effects.

COX-2-IN-30, a benzenesulfonamide derivative, is an orally active, dual inhibitor of cyclooxygenase-2 (COX-2; IC50 = 49 nM) and cyclooxygenase-1 (COX-1; IC50 = 10.4 μM), as well as 5-lipoxygenase (5-LOX; IC50 = 2.4 μM). Additionally, it inhibits the transmembrane isoforms of human carbonic anhydrase IX and XII with nanomolar class Ki values. Demonstrating analgesic and anti-inflammatory properties, COX-2-IN-30 is devoid of acute gastric effects, avoiding ulcerogenic activity [1].

(+)-Leucocyanidin, an isoform of leucocyanidin and potent anti-ulcerogenic agent, has been extracted from Litchi chinensis. This compound exhibits considerable protective properties in rat models against aspirin-induced gastric erosions [1].

Ferruginol has anti-plasmodial, leishmanicidal, anti-ulcerogenic, cardioprotective, anticancer, anti-oxidative and anti-inflammatory activities, it can induce apoptosis in non-small cell lung cancer (NSCLC) cells.